Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells
Open Access
- 1 April 2021
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 15, 1653-1666
Abstract
Background: Pulmonary arterial hypertension (PAH) is an incurable disease that urgently needs therapeutic approaches. Based on the therapeutic effects of fasudil and dichloroacetate (DCA) on PAH, we aimed to explore the effects and potential mechanism of a new salt, fasudil dichloroacetate (FDCA), in a SU5416 plus hypoxia (SuHx)-induced rat model of PAH. Methods: The rat model of PAH was established by a single subcutaneous injection of SU5416 (20 mg/kg) followed by hypoxia (10% O2) exposure for 3 weeks. FDCA (15, 45, or 135 mg/kg i.g. daily) or the positive control, bosentan (100 mg/kg i.g. daily), were administered from the first day after SU5416 injection. After 3-week hypoxia, hemodynamic parameters, and histological changes of the pulmonary arterial vessels and right ventricle (RV) were assessed. Additionally, in vitro, the effects of FDCA (50 μM), compared with equimolar doses of fasudil, DCA, or fasudil+DCA, on the proliferation, migration, and contraction of human pulmonary arterial smooth muscle cell (PASMC) under hypoxia (1% O2) were evaluated. Results: FDCA dose-dependently attenuated SuHx-induced PAH, with significant reductions in RV systolic pressure, pulmonary artery wall thickness, pulmonary vessel muscularization, perivascular fibrosis, as well as RV hypertrophy and fibrosis. In vitro, FDCA inhibited hypoxia-induced PASMC proliferation, migration, and contraction to a greater degree than fasudil or DCA alone by restoring mitochondrial function, reducing intracellular Ca2+, and inhibiting calcium/calmodulin-dependent kinase (Ca2+/CaMK) activity as well as Rho-kinase activity. Conclusion: FDCA ameliorates hypoxia-induced PASMC dysfunction by inhibiting both Ca2+/CaMK and Rho-kinase signaling pathways, as well as maintaining mitochondrial homeostasis, thus alleviating SuHx-induced PAH.Keywords
This publication has 40 references indexed in Scilit:
- New mechanisms of pulmonary arterial hypertension: role of Ca2+signalingAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial HypertensionCirculation, 2010
- Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafilEuropean Respiratory Journal, 2010
- Ca2+signaling in hypoxic pulmonary vasoconstriction: effects of myosin light chain and Rho kinase antagonistsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer GrowthCancer Cell, 2007
- Targeting of a Novel Ca+ 2 /Calmodulin-Dependent Protein Kinase II Is Essential for Extracellular Signal-Regulated Kinase–Mediated Signaling in Differentiated Smooth Muscle CellsCirculation Research, 2005
- Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell ApoptosisCirculation Research, 2004
- Ca 2+ -Dependent Activation of Rho and Rho Kinase in Membrane Depolarization–Induced and Receptor Stimulation–Induced Vascular Smooth Muscle ContractionCirculation Research, 2003
- Rho-dependent kinase is involved in agonist-activated calcium entry in rat arteriesThe Journal of Physiology, 2003
- Dysfunctional Voltage-Gated K + Channels in Pulmonary Artery Smooth Muscle Cells of Patients With Primary Pulmonary HypertensionCirculation, 1998